Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2008-007951-29-DK
EUCTR2008-007951-29-DK
Active, not recruiting
Not Applicable

Et fase II forsøg af neoadjuverende behandling med pegyleret liposomal doxorubicin (Caelyx®) og cyklofosfamid +/- trastuzumab med efterfølgende docetaxel til patienter med primær inoperabel og lokoregional avanceret cancer mammae (LABC). - Et videnskabeligt forsøg med kombinations kemoterapi før operation til patienter med brystkræft.

Herlev Hospital, Onkologisk Afd. R0 sitesJanuary 22, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsCaelyxSendoxanTaxotereHerceptin

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Herlev Hospital, Onkologisk Afd. R
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 22, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Female

Investigators

Sponsor
Herlev Hospital, Onkologisk Afd. R

Eligibility Criteria

Inclusion Criteria

  • •?Histologisk/cytologisk verificeret primær cancer mammae hos kvinder.
  • •?Primær tumor \> 50 mm (T3\-4,Nx,M0\) eller inoperabel lokoregional avanceret sygdom (Tx,N2\-3,M0\).
  • •?Alder mellem 18 og 75 år.
  • •?WHO Performance Status \= 2\.
  • •?Forventet levetid mere end 3 måneder.
  • •?Målbar (primærtumor(er) eller lymfeknudemetastaser) eller ikke\-målbar sygdom (inflammatorisk cancer mammae) i henhold til RECIST kriterier
  • •?”Adækvat” knoglemarvsfunktion defineret som:
  • •oleukocytter \= 3,0 x 109/L
  • •oneutrofile \= 1,5 x 109/L,
  • •othrombocytter \= 100 x 109/L

Exclusion Criteria

  • •?Anden malign sygdom i anamnesen (patienter som har været sygdomsfri i mindst 5 år eller patienter med basalcellekarcinom i hud eller karcinoma in situ cervix uteri i anamnesen indenfor de sidste 5 år kan dog indgå).
  • •?Behandling med et ikke\-godkendt lægemiddel eller en forsøgsmedicin inden for 30 dage før opstart af forsøgsbehandling.
  • •?Samtidig behandling med anden forsøgsmedicin.
  • •?Enhver evidens, i henhold til investigators bedømmelse, for svær eller ukontrolleret systemisk sygdom eller et signifikant laboratoriefund der gør det uønskeligt for patienten at deltage i forsøget.
  • •?Psykiske, familiære, sociale eller geografiske tilstande, som hindrer protokolcompliance.
  • •?Gravide eller ammende kvinder. Der skal foreligge negativ graviditetstest umiddelbart inden behandlingsstart for fertile kvinder.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
eoadjuvant DOS treatment for advanced esophageal cancer
JPRN-jRCTs041210023Kodera Yasuhiro45
Active, not recruiting
Not Applicable
?Estudio de fase II de tratamiento neoadyuvante con gemcitabina, Tarceva® y oxaliplatino, seguido de quimiorradioterapia con Tarceva® y gemcitabina en pacientes con adenocarcinoma pancreático de resecabilidad borderline?.PHASE II STUDY OF NEOADYUVANT TREATMENT WITH GEMCITSBINE, TARCEVA AND OXALIPLATIN FOLLOWED BY CHEMORADIOTERAPY WITH TARCEVA AND GEMCITABINE IN PATIENTS WITH PANCREAS ADENOCARCINOMA WITH BORDERLINE RESECABILITY - GEMERLOXA
EUCTR2010-021872-27-ESInstitut Català d?Oncologia (ICO)
Active, not recruiting
Not Applicable
Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study. - TVA studyRH- and Her2- operable breast cancer, in neoadjuvant situationMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancer
EUCTR2009-012853-39-FRCentre Jean Perrin
Active, not recruiting
Phase 1
Clinical trial for the evaluation of a new drug (cabozantinib) treatment given before having kidney surgery in patients with kidney cancer that is advanced or has spreadocally Advanced or Metastatic Renal Cell CarcinomaMedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-001201-93-ESFundación ONCOSUR50
Active, not recruiting
Phase 1
Phase II single-arm study evaluating abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist prior to receiving radical radiotherapy in high risk localised prostate carcinoma patientsHigh-risk prostate cancerMedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2014-001128-31-IECancer Trials Ireland36